Onychomycosis: Pathogenesis, diagnosis, and management

Clinical Microbiology Reviews

Volumn 11, Issue 3, 1998, Pages 415-429

  Elewski, Boni E ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ABDOMINAL PAIN; ANEMIA; ANTIBIOTIC SENSITIVITY; CANDIDA ALBICANS; CHOLESTASIS; DERMATOPHYTE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; FEVER; FUNGUS; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INJURY; LEUKOPENIA; LICHEN PLANUS; LIVER TOXICITY; MOULD; NAUSEA; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY; PRURITUS; PSORIASIS; REVIEW; TASTE DISORDER; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING; YEAST;

EID: 0031852718     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.11.3.415     Document Type: Review

References (68)

1. Aly, R. 1994. Ecology and epidemiology of dermatophyte infections. J. Am. Acad. Dermatol. 31:S21-S25.
2. Aly, R., and T. Berger. 1996. Common superficial fungal infections in patients with AIDS. Clin. Infect. Dis. 22(Suppl. 2):S128-S132.
3. André, J., and G. Achten. 1987. Onychomycosis. Int. J. Dermatol. 26:481-490.
4. Arenas, R, J. Dominguez-Cherit, and L. M. Fernandez. 1995. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int. J. Dermatol. 34:138-143.
5. Brautigam, M., S. Nolting, R. E. Schoff, and G. Weidinger for the Seventh Lamisil German Onychomycosis Study Group. 1995. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br. Med. J. 311:919-922.
6. Brodell, R. T., and B. E. Elewski. 1997. Superficial fungal infections: errors to avoid in diagnosis and treatment. Postgrad. Med. 101:279-287.
7. Brody, N. 1995. Cutaneous fungal infections: innovative treatment schedules with systemic agents. Int. J. Dermatol. 34:284-289.
8. Charif, M. A., and B. E. Elewski. 1997. A historical perspective on onychomycosis. Dermatol. Ther. 3:43-45.
9. Clayton, Y. M., and R. J. Hay. 1993. Epidemiology of fungal skin and nail disease: roundtable discussion held at Dermatology 2000, Vienna, 17 May 1993. Br. J. Dermatol. 130(Suppl. 4):9-11.
10. Clinical Courier. 1997. New strategies for the effective management of superficial fungal infections. Clin. Courier 16:2-3.
11. Clinical Courier. 1994. Superficial fungal infections: diagnosis and management of onychomycosis. Clin. Courier 12:2.
12. Cohen, J. L., R. K. Scher, and A. S. Pappert. 1992. The nail and fungus infections, p. 106-122. In B. Elewski (ed.), Cutaneous fungal infections. Igaku-Shoin Inc., New York, N.Y.
13. Davies, R. R. 1980. Griseofulvin, p. 149-182. In D. C. E. Speller (ed.), Antifungal chemotherapy. John Wiley & Sons Ltd., Chichester, England.
14. De Backer, P., P. De Keyser, C. De Vroey, and E. Lesaffre. 1996. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day - a double-blind comparative trial. Br. J. Dermatol. 134(Suppl. 46):16-17.
15. Decroix, J., P. Fritsch, A. Picoto, W. Thrülimann, and H. Degreef. 1997. Short-term itraconazole versus terbinafine in the treatment of superficial dermatomycosis of the glabrous skin (tinea corporis or cruris). Eur. J. Dermatol. 7:353-357.
16. De Doncker, P. 1997. Pharmacokinetics of oral antifungal agents. Dermatol. Ther. 3:46-57.
17. De Doncker, P., J. Decroix, G. E. Pierard, D. Roelant, R. Woesternborghs, P. Jacqmin, F. Odds, A. Heremans, P. Dockx, and D. Roseeuw. 1996. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch. Dermatol. 132:34-41.
18. Del Rosso, J. Q. 1997. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J. Am. Osteopath. Assoc. 97:339-345.
19. Del Rosso, J. Q., and A. K. Gupta. 1997. Oral antifungal agents: recognition and management of adverse reactions. Today's Ther. Trends 15:75-84.
20. Dompmartin, D., A. Dompmartin, A. M. Deluol, E. Grosshans, and J. P. Coulaud. 1990. Onychomycosis and AIDS: clinical and laboratory findings in 62 patients. Int. J. Dermatol. 29:337-339.
21. Drake, L., D. Babel, D. M. Stewart, P. Rich, M. R. Ling, D. Breneman, R. K. Sher, A. G. Martin, D. M. Pariser, R. J. Pariser, C. N. Ellis, D. Friedman, H. I. Katz, C. J. McDonald, J. Muglia, R. C. Savin, G. Webster, B. E. Elewski, J. J. Leyden, A. D. Monroe, E. H. Tschen, J. M. Hanifin, M. R. Morman, J. L. Shupack, N. Levine, N. J. Lowe, W. F. Bergfeld, C. Camisa, D. S. Feingold, N. Konnikov, R. B. Odom, R. Aly, and D. L. Greer. A placebo-controlled, randomized, double-blind trial of once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J. Am. Acad. Dermatol., in press.
22. Drake, L. A., S. M. Dinehart, E. R. Farmer, R. W. Goltz, G. F. Graham, M. K. Hordinsky, C. W. Lewis, D. M. Pariser, J. W. Skouge, S. B. Webster, D. C. Whitaker, B. Butler, and B. J. Lowery. 1996. Guidelines of care for superficial mycotic infections of the skin: onychomycosis. J. Am. Acad. Dermatol. 34:116-121.
23. Dwyer, C. M., M. I. White, and T. S. Sinclair. 1997. Cholestatic jaundice due to terbinafine. Br. J. Dermatol. 136:968-981.
24. Elewski, B. E. 1993. Mechanisms of action of systemic antifungal agents. J. Am. Acad. Dermatol. 28:S28-S34.
25. Elewski, B. E. 1995. Clinical pearl: diagnosis of onychomycosis. J. Am. Acad. Dermatol. 32:500-501.
26. Elewski, B. E. 1997. Large scale epidemiological study of the causal agents of onychomycosis: mycological findings from the multicenter onychomycosis study of terbinafine. Arch. Dermatol. 133:1317-1318.
27. Elewski, B. E., and M. A. Charif. 1997. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch. Dermatol. 133:1172-1173. (Letter.)
28. Elewski, B. E., and R. J. Hay. 1996. Update on the management of onychomycosis: highlights of the third annual international summit on cutaneous antifungal therapy. Clin. Infect. Dis. 23:305-313.
29. Elewski, B. E., R. K. Scher, R. Aly, R. Daniel III, H. E Jones, R. B. Odom, N. Zaias, and M. L. Jacko. 1997. Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis 59:217-220.
30. Elewski B. E., M. G. Rinaldi, and I. Weitzman. 1995. Diagnosis and treatment of onychomycosis. a clinician's handbook. Gardiner-Caldwell SynerMed, Califon, N.J.
31. Ellis, D. H., A. B. Watson, J. E. Marley, and T. G. Williams. 1997. Non-dermatophytes in onychomycosis of the toenails. Br. J. Dermatol. 136:490-493.
32. Ellis, D. H., J. E. Marley, A. B. Watson, and T. G. Williams. 1997. Significance of non-dermatophyte molds and yeasts in onychomycosis. Dermatology 194(Suppl. 1):40-42.
33. Fraki, J., H. T. Heikkilä, M. O. Kero, K. E. Kuokkanen, R. O. Oksman, T. T. Rantanen, S. S. Saari, M. L. Sten, S. H. A. Stubb, and P. E. Uggeldahl. 1991. Fluconazole in the treatment of onychomycosis: an open, non-comparative study with oral 150 mg fluconazole once weekly, abstr. 14. In Dermatology 2000 (symposium).
34. Goodfield, M. J. D. 1992. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br. J. Dermatol. 126(Suppl. 39):33-35.
35. Gupta, A. K. 1996. The development of green vision in association with terbinafine therapy. Arch Dermatol. 132:845-846.
36. Gupta, A. K., J. B. Kopstein, and N. H. Shear. 1997. Hypersensitivity reaction to terbinafine. J. Am. Acad. Dermatol. 36:1018-1019.
37. Gupta, A. K., R. G. Sibbald, C. W. Lynde, P. R. Hull, R. Prussick, N. H. Shear, P. De Doncker, C. R. Daniell III, and B. E. Elewski. 1997. Onychomycosis in children: prevalence and treatment strategies. J. Am. Acad. Dermatol. 36:395-402.
38. Havu, V., H. Brandt, H. Heikkilä, A. Hollne, R. Oksman, T. Rantanen, S. Saari, S. Stubb, K. Turjanmaa, and T. Piepponen. 1997. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br. J. Dermatol. 136: 230-234.
39. Hay, R. J. 1992. Fungal skin infections. Arch. Dis. Child. 67:1065-1067
40. Heikkalä, H., and S. Stubbs. 1995. The prevalence of onychomycosis in Finland. Br. J. Dermatol. 133:699-701.
41. Honeyman, J. F., F. S. Talarico, L. H. F. Arruda, A. C. Pereira, Jr., J. R. Santamaria, E. M. Souza, A. Woscoff, F. R. Amorim, C. R. de la Parra, M. Y. Enokihara, M. F. Gavazoni, H. W. Gubelin, S. P. Rosa, M. A. G. Turini, and M. A. Vitale. 1997. Itraconazole versus terbinafine (LAMISIL®): which is better for the treatment of onychomycosis? J. Eur. Acad. Dermatol. Venereol. 9:215-221.
42. Janssen Pharmaceutica. 1997. Itraconazole package insert. Janssen Pharmaceutica, Titusville, N.J.
43. Janssen Pharmaceutica. 1997. Ketoconazole package insert. Janssen Pharmaceutica, Titusville, N.J.
44. Junquiera, L. C., J. Carneiro, and R. O. Kelley. 1995. Basic histology, 8th ed., p. 353-355. Appleton & Lange, Stamford, Conn.
45. Kuokkanen, K., and S. Alava. 1993. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J. Dermatol. Treat. 3:115-117.
46. Matthieu, L., P. De Doncker, G. Cauwenbergh, R. Woestenborghs, V. van de Velde, P. A. Janssen, and P. Dockx. 1991. Itraconazole penetrates the nail via the nail matrix and the nail bed: an investigation in onychomycosis. Clin. Exp. Dermatol. 16:374-376.
47. Nolting, S., M. Brautigam, and G. Weidinger. 1994. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br. J. Dermatol. 130(Suppl. 43):16-21.
48. 47a.Novartis Pharmaceuticals Corporation. 1997. Terbinafine package insert. Novartis Pharmaceuticals Corp., E. Hanover, N.J.
49. Odom, R., C. R. Daniel III, and R. Aly. 1996. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J. Am. Acad. Dermatol. 35:110-111.
50. Odom, R. B., R. Aly, R. K. Scher, C. R. Daniel III, B. E. Elewski, N. Zaias, R. DeVillez, M. Jacko, N. Oleka, and B. L. Moskovitz. 1997. A multicenter-placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J. Am. Acad. Dermatol. 36:231-235.
51. Ortho Diagnostics. 1997. Griseofulvin package insert. Ortho Dermatologic Division, Raritan, N.J.
52. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
53. Rippon, J. W. 1988. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes, 3rd ed., p. 169-275. The W. B. Saunders Co., Philadelphia, Pa.
54. Roseeuw, D., and P. De Doncker. 1993. New approaches to the treatment of onychomycosis. J. Am. Acad. Dermatol. 29:S45-S50.
55. Scher, R. K. 1990. Diseases of the nails, p. 736-742. In H. Conn (ed.), Current therapy. The W. B. Saunders Co., Philadelphia, Pa.
56. Scher, R. K. 1996. Onychomycosis: a significant medical disorder. J. Am. Acad. Dermatol. 35(Part 2):S2-S5.
57. Scher, R. K., D. Breneman, P. Rich, R. C. Savin, D. S. Feingold, N. Konnikov, J. L. Shupack, S. Pinnell, N Levine, N. J. Lowe, R. Aly, R. B. Odom, D. L. Greer, M. R. Morman, A. D. Monroe, E. H. Tschen, B. E. Elewski, and E. B. Smith. A placebo-controlled, randomized, double-blind trial of onceweekly fluconazole (ISO mg, 300 mg, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J. Am. Acad. Dermatol., in press.
58. Sigler, L., and H. Congly. 1990. Toenail infection caused by Onychocola canadensis gen. et sp, nov. J. Med Vet. Mycol. 28:405-17.
59. Summerbell, R. C, 1997. Epidemiology and ecology of onychomycosis. Dermatology 194(Suppl. 1):32-36.
60. Summerbell, R. C., J. Kane, and S. Krajden. 1989. Onychomycosis, tinea pedis, and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 32:609-619.
61. Tausch, I., M. Brautigam, G. Weidinger, T. C. Jones, and the Lagos V Study Group. 1997. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. Br. J. Dermatol. 136:737-742.
62. Tosti, A., B. M. Piraccini, C. Stinchi, N. Venturo, F. Bardazzi, and M. D. Colombo. 1996. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J. Am. Acad. Dermatol. 34:595-600.
63. Van der Schroeff, J. G., P. K. S. Cirkel, M. B. Crijns, T. J. A. Van Kijk, F. J. Govaert, D. A. Groeneweg, D. J. Tazclaar, R. F. E. Dewitt, and J. Wuite. 1992. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br. J. Dermatol. 126(Suppl. 39):36-39.
64. Weitzman, I., and R. C. Summerbell. 1995. The dermatophytes. Clin. Microbiol. Rev. 8:240-259.
65. Winn, W. C., Jr. 1996. Mycotic diseases, p. 1210-1251. In J. B. Henry (ed.), Clinical diagnosis and management. The W. B. Saunders Co., Philadelphia, Pa.
66. Zaias, N. 1972. Onychomycosis. Arch. Dermatol. 105:263-274.
67. Zaias, N., B. Glick, and G. Rebell. 1996. Diagnosing and treating onychomycosis. J. Fam. Pract. 42:513-518.
68. Zaias, N., A. Tosti, G. Rebell, R. Morelli, F. Bardazzi, H. Bieley, N. Zaiac, B. Glick, B. Paley, M. Allevato, and R. Baran. 1996. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. J. Am. Acad. Dermatol. 34(2 Pt 1):302-304.